Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharmaceutical Company and Amylin Pharmaceuticals have mutually terminated their worldwide agreement signed in October 2009 to co-develop and commercialize anti-obesity compounds.
Subscribe to our email newsletter
In August 2011, the companies decided to suspend the pramlintide/metreleptin investigational combination therapy development.
The decision was based on a commercial re-assessment of the program, which had been in phase II development of a twice-a-day injection formulation.
Japan-based Takeda expects to carry on enhancing R&D activities in the area of obesity in addition to other main therapeutic aspects.